Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine

Liver Transplantation

Volumn 13, Issue 11, 2007, Pages 1570-1575

  Lobritto, Steven J ^a   Rosenthal, Philip ^b   Bouw, Rene ^c   Leung, Mimi ^d   Snell, Paul ^c   Mamelok, Richard D ^e  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ROCHE PRODUCTS LTD   (United Kingdom)

^d HOFFMANN LA ROCHE INC   (United States)

^e Mamelok Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE GRAFT REJECTION; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG RESPONSE; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LIVER TRANSPLANTATION; MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION;

AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LIVER TRANSPLANTATION; MYCOPHENOLIC ACID;

EID: 36448932767     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21274     Document Type: Article

References (21)

1. Gavlik A, Demirbas A, Tsaroucha A, et al. Mycophenolate mofetil rescue therapy in liver transplant recipients: an extended follow-up. Transplant Proc 1997;29:2971.
2. Wiesner R, Rabkin J, Klintmalm G, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001;7:442.
3. Fisher RA, Stone JJ, Wolfe LG, et al. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation. Clin Transplant 2004;18:463.
4. Wiesner RH, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Lake JR. Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl 2005; 11:750.
5. Toyoki Y, Renz JF, Mudge C, Ascher NL, Roberts JP, Rosenthal P. Allograft rejection in pediatric liver transplantation: comparison between cadaveric and living related donors. Pediatr Transplant 2002;6:301.
6. Renz JF, Lightdale J, Mudge C, et al. Mycophenolate mofetil, microemulsion cyclosporine, and prednisone as primary immunosuppression for pediatric liver transplant recipients. Liver Transpl Surg 1999;5:136.
7. Chardot C, Nicoluzzi JE, Janssen M, et al. Use of mycophenolate mofetil as rescue therapy after pediatric liver transplantation. Transplantation 2001;71:224.
8. Evans HM, McKiernan PJ, Kelly DA. Mycophenolate mofetil for renal dysfunction after pediatric liver transplantation. Transplantation 2005;79:1575.
9. Jain A, Venkataramanan R, Hamad IS, et al. Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. J Clin Pharmacol 2001;41:268.
10. Brunet M, Cirera I, Martorell J, et al. Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. Transplantation 2006;81:541.
11. McDiarmid SV. Mycophenolate mofetil in liver transplantation. Clin Transplant 1996;10(Pt 2):140.
12. Jacqz-Aigrain E, Khan Shaghaghi E, Baudouin V, et al. Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. Pediatr Nephrol 2000;14:95.
13. Payen S, Zhang D, Maisin A, et al. Population pharmacokinetics of mycophenolic acid in kidney transplant pediatric and adolescent patients. Ther Drug Monit 2005;27: 378.
14. Bunchman T, Navarro M, Broyer M, et al. The use of mycophenolate mofetil suspension in pediatric renal allograft recipients. Pediatr Nephrol 2001;16:978.
15. Pisupati J, Jain A, Burckart G, et al. Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. J Clin Pharmacol 2005:45:34.
16. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998;34:429.
17. Aw MM, Brown NW, Itsuka T, et al. Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. Liver Transpl 2003;9:383.
18. Arns W, Cibrik DM, Walker RG, et al. Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature. Transplantation 2006;82:1004.
19. Venkataramanan R, Shaw LM. Therapeutic monitoring of mycophenolic acid in liver transplant patients. Liver Transpl 2004;10:503.
20. Filler G, Zimmering M, Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol 2000;14:100.
21. Pharmacokinetics of total and free mycophenolic acid (MPA) when mycophenolate mofetil (MMF) is administered with low-dose tacrolimus, low-dose cyclosporine, low-dose sirolimus or standard-dose cyclosporine in renal transplantation. Results of the Symphony PK substudy. Transplantation 2006;82(Suppl 2):345.